Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Antitumor effects of the hydralazine-valproate combination in lymphoma

ABSTRACT: Epigenetic alterations are common in both B cell and T cell lymphomas. These contribute to lymphomagenesis and treatment resistance, hence epigenetic therapy is being investigated. We evaluated the effects of the DNA-methyltrasferase inhibitor hydralazine and the histone deacetylase inhibitor valproate in T-cell lymphoma HuT78 cells and B-cell lymphoma Raji cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE168790 | GEO | 2021/03/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

Project description:As a number of epigenetic alterations have been described in cervical cancer which may participate in the development and progression of this tumor, and the primary treatment for locally advanced disease is concurrent chemoradiation, we wanted to evaluate the efficacy and safety of hydralazine and valproate added to radiation and cisplatin. In addition, the transcriptome changes induced by the epigenetic drugs were also evaluated. Keywords: Cervical Cancer, epigenetic therapy, valproate, hydralazine, transcriptional response, epigenetic drugs

2007-07-31 | GSE8604 | GEO

Antitumor effects of the hydralazine-valproate combination in lymphoma

Project description:Antitumor effects of the hydralazine-valproate combination in lymphoma

| PRJNA713994 | ENA

Gene Expression Profiles of Epigenetic treatment in primary breast cancer.

Project description:Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine plus the HDAC inhibitor magnesium valproate were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy. Keywords: Epigenetic treatment, Hydralazine, valproate, breast cancer

2006-11-18 | GSE6304 | GEO

Methyltransferase Inhibitors Restore SATB1 Protective Activity Against Cutaneous T cell Lymphoma

Project description:We report Chromatin Immunoprecipitation for the histone modifications H3K27ac, H3K27m3 and H3K9m3 in human leukemia and lymphoma cell lines HuT78, Jurkat, K562, and RAJI to ascertain the regulatory landscape of in regards to transcriptional repression and activation.

2022-10-26 | GSE159962 | GEO

Growth inhibition and transcriptional effects of ribavirin in lymphoma

Project description:The cutaneous T-cell lymphoma Hut78 was treated with ribavirin for 120 h, and the gene expression of the treated cells was compared with respect to the expression of the cells without treatment. We evaluated the effect of treatment with ribavirin upon gene expression in a cutaneous T-cell lymphoma model, Hut78. Ribavirin treatment decreased approximately 90% of the viability of Hut78 cells. A complete genomic analysis of transcriptomic status after treatment with ribavirin of cutaneous T cell lymphoma Hut78 revealed an impact on the overall expression of transcripts.

2020-08-02 | GSE118066 | GEO

Effect of Sodium Valproate on Rat Primary Hepatocytes.

Project description:This study provides an evaluation of changes in gene expression associated with sodium valproate treatment of rat hepatocytes in vitro. Primary rat hepatocytes were treated for 24 and 48 hours with two doses (500 uM and 10 mM) of sodium valproate and water vehicle control. Five replicates of each treatment were performed. Cells were then extracted and RNA processed for microarray analysis.

2012-08-28 | GSE40338 | GEO

Homo sapiens

Project description:Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

| PRJNA101771 | ENA

Profile of gene expression in K562 cells exposed to 2 mM sodium valproate for 12 hours using Agilent SurePrint G3 Human GE 8x60K Microarray.

Project description:To explore the mechanism underlying anti-leukaemia effect of sodium valproate, the growth and survival of the K562 cell line were investigated using the Annexin V/PI dual staining method. Global profiles of gene expression in K562 cells exposed to sodium valproate were assessed using gene expression microarray and validated by qRT-PCR. Gene ontology analysis was performed to establish the function of differentially expressed genes. The differentially expressed genes identified by using gene expression array were further used to query the CMAP database to retrieve a ranked list of compounds that act on the same intracellular targets as sodium valproate. A significant increase in cell apoptosis was observed in valproate exposed K562 cells using flow cytometry. A total of 706 transcripts were identified as being significantly differentially expressed. Eight differentially expressed genes that might be involved in apoptosis were verified by qRT-PCR. The significant enrichment analysis of gene ontology terms for the differentially expressed genes revealed that these genes are involved in many important biological processes such as apoptosis. The connectivity map analysis showed gene expression profile in K562 cells exposed to sodium valproate observed in this study was most similar to that of HDACi and PI3K inhibitor in the connectivity map database, suggesting that sodium valproate might exert anti-leukaemic action by inhibiting HDAC as well as inhibiting PI3K pathway. In conclusion, the data obtained in this study might provide the ground for further studies to elucidate the molecular and therapeutic potential of VPA in leukaemia treatment.

2011-11-11 | GSE32189 | GEO

Profile of gene expression in K562 cells exposed to 2 mM sodium valproate for 12 hours using Agilent SurePrint G3 Human GE 8x60K Microarray.

2011-11-11 | E-GEOD-32189 | biostudies-arrayexpress

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Project description:The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

| 5791 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data